Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00209092 · ClinicalTrials.gov registry record · Phase 2

Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
51
Enrollment target
19
Study locations

NCT00209092 is a Phase 2 study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 51 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 19 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00209092, a Phase 2 study of Breast Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
51 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Capecitabine

Study Locations (19)

Georgia

  • Grady Memorial Hospital - Atlanta
  • Emory Crawford Long Hospital - Atlanta
  • Emory University Winship Cancer Institute - Atlanta
  • Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300 - Augusta
  • Augusta Oncology Associates, PC 3696 Wheeler Road - Augusta
  • WellStar Health System-Georgia Cancer Specialists - Austell
  • WellStar Health System-Northwest Georgia Oncology Center, PC - Austell
  • WellStar Health System-Northwest Georgia Oncology Center, PC - Carrollton
  • John B. Amos Cancer Center - Columbus
  • Suburban Hematology-Oncology Associates, PC - Duluth
  • South Atlanta Hematology-Oncology Group - East Point
  • Suburban Hematology-Oncology Associates, PC - Lawrenceville
  • Central Georgia Cancer Care, PC - Macon
  • WellStar Health System-Georgia Cancer Specialists - Marietta
  • WellStar Health System-Northwest Georgia Oncology Center, PC - Marietta
  • South Atlanta Hematology-Oncology Group - Riverdale
  • Suburban Hematology-Oncology Associates, PC - Snellville
  • South Atlanta Hematology-Oncology Group - Stockbridge
  • Central Georgia Cancer Care, PC - Warner Robins

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2006-08
Est. Completion 2012-10
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00209092

The ClinicalTrials.gov registry entry for NCT00209092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT00209092 reports 19 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT00209092 about?

NCT00209092 is a clinical study titled "Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer". The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

What is the current status of trial NCT00209092?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2006-08. Estimated completion is 2012-10.

What conditions does trial NCT00209092 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00209092?

The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG).

Who is sponsoring clinical trial NCT00209092?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00209092 being conducted?

This trial has 19 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.